Cayman 9-Amino Camptothecin; Purity- Greater Than Or Equal To 95%

Zardaverine is a dual inhibitor of phosphodiesterase 3 (PDE3) and PDE4 (IC₅₀s = 0.617 and 1.738 μM, respectively, for the rat cardiac ventricle enzymes). It is selective for PDE3 and PDE4 over PDE1B, PDE2, and PDE5 (IC₅₀s = >138 μM for all). Zardaverine inhibits aggregation of human platelets induced by ADP (Item No. ), platelet-activating factor (PAF), collagen, arachidonic acid (Item Nos. | | ), or prostaglandin E₁ (PGE₁; Item No. ) and ADP (IC₅₀s = 1.5-16.2 μM). It inhibits zymosan-induced superoxide anion release from human polymorphonuclear (PMN) cells (IC₅₀ = 0.4 μM). Zardaverine (10 μmol/kg) decreases lung resistance and increases dynamic compliance in a rat model of acetylcholine-induced bronchospasm. It decreases the viability of HeLa, COLO 741, NCI H2122, and A2058 cells that endogenously express high levels of PDE3A (IC₅₀s = 0.032, 0.027, 0.26, and 0.13 μM, respectively), but is inactive against a panel of eight cancer cell lines that express low levels of PDE3A (IC₅₀s = >16 μM for all).

WARNING This product is not for human or veterinary use.